InvestorsHub Logo
Followers 7
Posts 1173
Boards Moderated 0
Alias Born 11/13/2018

Re: couldbebetter post# 236574

Sunday, 12/22/2019 9:54:53 AM

Sunday, December 22, 2019 9:54:53 AM

Post# of 424398
Vascepa and Amarin now have a CVOT behind them and an approved drug for a huge indication. A huge marketing campaign is going to begin soon that is going to be able to tell everyone about the reduction in stroke and heart attack. Amarin is going to go full board at it.

The worthless products have been on the market all along and sales of Vascepa have ramped up very well over the last year. The script growth will go parabolic once the insurance coverage changes and the expanded label commercials that show CVOT benefit begin.

Sales reps have over time become less and less a part of the medical system. Physicians are often parts of large chains and are restricted from seeing sales reps or they refuse to on their own. The internet has in so many ways replaced what sales reps used to do. the vascepahcp.com website will tell a physician all they need to know to prescribe. The drug is a very safe drug without problems with interactions with other medications. Any physician that has heard of it can figure out how to prescribe it without needing a sales reps. Physicians here who whine and complain they can't get a rep to visit them are just wanting to be pampered. It's not that they don't know how to prescribe it, they just want to be pampered.

Standard of Care is going to go a long way toward helping the launch. I would imagine the ad campaigns will be able to include some of that information.

I think you are overthinking the deceitful products, they do not have a multimillion dollar ad campaign underway. Education will will over deceit. A small percent may fall for it but the numbers will be staggering with time.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News